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Abstract
Rationale
The Spanish guideline for COPD (GesEPOC) recommends COPD treatment according to
four clinical phenotypes: non-exacerbator phenotype with either chronic bronchitis or emphy-
sema (NE), asthma-COPD overlap syndrome (ACOS), frequent exacerbator phenotype with
emphysema (FEE) or frequent exacerbator phenotype with chronic bronchitis (FECB). How-
ever, little is known on the distribution and outcomes of the four suggested phenotypes.
Objective
We aimed to determine the distribution of these COPD phenotypes, and their relation with
one-year clinical outcomes.
Methods
We followed a cohort of well-characterized patients with COPD up to one-year. Baseline
characteristics, health status (CAT), BODE index, rate of exacerbations and mortality up to
one year of follow-up were compared between the four phenotypes.
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Results
Overall, 831 stable COPD patients were evaluated. They were distributed as NE, 550
(66.2%); ACOS, 125 (15.0%); FEE, 38 (4.6%); and FECB, 99 (11.9%); additionally 19
(2.3%) COPD patients with frequent exacerbations did not fulfill the criteria for neither FEE
nor FECB. At baseline, there were significant differences in symptoms, FEV1 and BODE
index (all p<0.05). The FECB phenotype had the highest CAT score (17.1±8.2, p<0.05
compared to the other phenotypes). Frequent exacerbator groups (FEE and FECB) were
receiving more pharmacological treatment at baseline, and also experienced more exacer-
bations the year after (all p<0.05) with no differences in one-year mortality. Most of NE
(93%) and half of exacerbators were stable after one year.
Conclusions
There is an uneven distribution of COPD phenotypes in stable COPD patients, with signifi-
cant differences in demographics, patient-centered outcomes and health care resources
use.
Introduction
COPD is a heterogeneous disease characterized by chronic airflow obstruction in which exacer-
bations and comorbidities, among other clinical factors, can contribute to its severity [1]. In
order to approach this heterogeneity, an attempt to group patients with similar characteristics
that could be associated to a differential clinical outcome has been done by using the term clini-
cal phenotype [2]. Clear examples of COPD phenotypes associated to different outcomes have
been recently shown, such as the frequent exacerbator [3] or the overlap COPD and asthma
phenotypes [4]. However, international guidelines, such as the Global Initiative in Obstructive
Lung Diseases (GOLD), do not recognize these clinical characteristics when addressing the
best therapeutic options to treat these patients, relying this decision on lung function, symp-
toms and history of exacerbations. However, the overwhelming evidence that supports differ-
ent response to therapy in patients with specific characteristics (inhaled steroids in patients
with eosinophilia [5], roflumilast in patients with chronic bronchitis [6], etc) raises the need
for a more comprehensive approach to treat these patients.
The new Spanish Guideline for COPD (GesEPOC) [7] proposes a different algorithm for
pharmacologic treatment based on four phenotypes: the non-exacerbator (NE) with either
emphysema or chronic bronchitis phenotype; the COPD and Asthma overlap phenotype
(ACOS); the frequent exacerbator with emphysema (FEE) and the frequent exacerbator with
chronic bronchitis (FECB). Severity is assessed by the BODE or the BODEX indexes, and phar-
macologic treatment is adjusted according to phenotype and severity. A stepwise approach in
the pharmacologic treatment is proposed, with long-acting bronchodilators as the mainstay of
treatment, but differentiating specific therapies for the different phenotypes adjusted for sever-
ity (inhaled steroids from early stages in ACOS, roflumilast for FECB, etc). This innovative
approach has been adopted after the consensus of the different players in the health-care man-
agement of COPD patients, namely respiratory medicine specialists, primary care, and internal
medicine—by their respective scientific societies- and supported by the health-care authorities.
Miravitlles at al have recently shown that different phenotypes showed different demographic
and clinical characteristics [8]. However, long-term stability of these phenotypes is largely
unknown.
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In order to explore the distribution of these four COPD phenotypes and their differences in
terms of demographic data and one-year patient related outcomes, data from a Spanish multi-
center prospective cohort with multidimensional evaluation of COPD patients (COPDHistory
Assessment In SpaiN (CHAIN)) were analyzed.
Methods
All patients signed an informed, written consent form, which was previously approved by each
one of the Ethics Committee in every participating center. The study was approved by the Eth-
ics Committee of the Balearic Islands.
Methodology and recruitment strategy has been published elsewhere [9]. Briefly, COPD
was defined by smoking history10 pack-years and a post-bronchodilator FEV1/FVC<0.7
after 400 μg of inhaled albuterol. The main goal of this prospective observational study is to
perform a multidimensional evaluation of the evolution of COPD patients to better define its
natural history and potential clinical phenotypes (ClinicalTrials.gov Identifier: NCT01122758).
The recruitment periodwas between January 15, 2010 and March 31, 2012. Data analyzed in
the present study come from the baseline and one year assessments. Demographic and clinical
data were evaluated at baseline and at first annual visit: anthropometric data (age, gender and
BMI), comorbidities (Charlson index), smoking history, dyspnea (mMRC scale), exacerbations
in the previous year, health status by the validated Spanish version of the COPD Assessment
Test (CAT) and Clinical COPD (CCQ) questionnaire, anxiety and depression (HAD question-
naire), pharmacologic treatments, respiratory function (arterial blood gases, spirometry, lung
volume and diffusion capacity), exercise capacity by six-minute walk distance (6MWD) and
BODE index. Data of the patients were anonymized in a database with a hierarchical access
control in order to guarantee secure information access.
Clinical and physiological measurements
Trained staff in a personal interviewobtained the following information at the time of recruitment
and at yearly appointments: age, gender and the bodymass index (BMI), calculated as the weight
in kilograms divided by height in meters. A specific questionnaire was used to determine smoking
status (current or former) and smoking history (pack-years). Chronic bronchitis was defined by
the presence of cough and sputum production during three consecutivemonths in two consecutive
years. The presence or absence of emphysema was considered according to radiological (presence
of emphysema in CT scan as reported by the local radiologist) and/or functional criteria
(DLCO<80%). The presence of comorbidities was evaluated by the Charlson index.
Pulmonary function tests were performed following ATS guidelines [10]. The diffusion
capacity for carbonmonoxide (DLCO) was determined by the single breath technique follow-
ing the ERS/ATS guidelines. The 6MWD test was measured as the better of two walks sepa-
rated by at least 30 minutes. Dyspnea was evaluated by the modifiedMedical Research Council
(mMRC) scale. The percentage of forced expiratory volume at first second (FEV1%), BMI,
6MWD and MMRC values were integrated into the BODE index as previously described [11].
Exacerbations were defined by use of antibiotics (mild exacerbations), steroids or both (moder-
ate exacerbations) captured from a diary of exacerbations (handled between the patient, the
primary care physician and the chest physician) or admission to hospital (severe exacerbations)
related to worsening of respiratory symptoms.
Definition of phenotype
The NE phenotype was considered if the patient had less than two exacerbations requiring
antibiotics, oral steroids or hospitalization in the preceding 12 months, regardless of the
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presence of emphysema or criteria for chronic bronchitis. ACOS definitionwas based on previ-
ously published criteria [12]. Accordingly, ACOS was defined in the presence of one major cri-
teria (namely, a previous history of asthma, or a bronchodilator response to albuterol higher
than 15% or 400 ml) or two minor criteria (blood eosinophils>5%, immunoglobuline E>100
IU, or two separated bronchodilator responses to albuterol higher than 12% and 200 ml).
The frequent exacerbator phenotype was defined by the presence of, at least, two exacerba-
tions requiring antibiotics, oral steroids or one hospitalization in the preceding 12 months and
separated by at least four weeks. Frequent exacerbator were also divided according to the pres-
ence of chronic bronchitis (defined by the presence of cough and sputum production for at
least 3 months during two consecutive years) regardless of the presence of emphysema (CB
phenotype), the presence of emphysema in the absence of chronic bronchitis (FEE phenotype),
or the presence of ACOS criteria. If patients with frequent exacerbations did not fit into any of
the previously set phenotypes were designated as group 0. The distribution of the four different
phenotypes according to these criteria were analyzed following a proposed algorithm (Fig 1).
Fig 1. Flow-chart and algorithm of patients and phenotypes.
doi:10.1371/journal.pone.0160770.g001
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Patients and variables
COPD patients participating in the CHAIN cohort were included. Association between base-
line phenotype and one-year clinical outcomes, mainly CAT, FEV1, mMRC score, BODE and
exacerbations during the follow-up periodwere evaluated.
Statistical analysis
Data are summarized as relative frequencies for categorical variables, mean (SD) for normally
distributed scale variables and median (5th‒95th percentile) for ordinal or non-normal scale
variables. Comparisons were performed using Pearson’s Chi-square for categorical variables
and ANOVA for continuous variables, according to the variables type and distribution. Stan-
dard Kaplan-Meier statistics were applied, including a Coxmodel to determine the significance
of survival probabilities by covariates (age, gender and GOLD severity) of COPD patients
according to different phenotypes. Significance level was established as a two-tailed p value
<0.05. Analyses were performed using SPSS statistic package version 20.0 Inc. (Chicago, IL,
USA).
Results
Distribution of phenotypes
Eight hundred and thirty-one patients included in the CHAIN cohort were classified in differ-
ent phenotypes according to a proposed algorithm (Fig 1). Most patients were classified as
non-exacerbator phenotype (66.2%), 15% fulfilled criteria for ACOS, and the remaining 18.8%
were classified as exacerbator phenotype. Of these, 63.5% of patients were FECB phenotype,
24.3% were FEE phenotype and 12.2% (19 patients, 2.3% of the entire COPD population) were
frequent exacerbators that did not fulfill criteria for either chronic bronchitis or emphysema
(group 0).
Distribution of phenotypes by age and gender showed a marked increase in the exacerbator-
type phenotype (FEE, FECB or 0) with age (p<0.05), especially in women (Fig 2).
Characteristics of patients according to phenotype
Baseline socio-demographic and clinical characteristics are shown in Table 1.
Patients in different phenotypes were predominantly male and showed similar age, smoking
history, BMI, or spirometric severity (p>0.05). There were statistically significant differences
in symptoms, CAT score, FEV1, FEV1/FVC and BODE index between groups, being the FECB
phenotype the most symptomatic with higher BODE score. By definition, and as a consequence
of algorithm application, exacerbations or the presence of emphysema were different among
groups. Patients with frequent exacerbations without criteria for chronic bronchitis or emphy-
sema (group 0) were not different in clinical characteristics other than cough and sputum pro-
duction or the presence of emphysema that were generated by the application of the algorithm.
Comorbidities,measured by the Charlson index, were similar among all groups. Only previous
diagnosis of asthma, as a sole criterion to define ACOS, was different with the other pheno-
types. Anxiety and depression were also present in similar proportion among the different phe-
notypes. Again, patients in group 0 did not show a differential pattern of comorbidities
(Table 2).
Pharmacological treatments for COPD were statistically different among the different phe-
notypes, being the exacerbator phenotypes (FEE and FECB) those with the highest use of respi-
ratory drugs (Table 3), while those in group 0 had the highest anticholinergics and
theophylline use.
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Longitudinal assessment
Four hundred and ninety-four patients were re-studied after one year, 333 patients from the
non-exacerbator phenotype, 77 from ACOS and 84 from the exacerbator phenotypes. There
were 270 drop-outs and 67 deaths during follow-up.
After one-year of follow-up patients showed statistically significant differences in CAT-
score (p<0.05) and non-significant differences in BODE index (Fig 3) compared with their
baseline characteristics. Smoking cessation was observed in 12,6% of the population.
Moderate-severe exacerbation rates remained also significantly different among pheno-
types, with a higher proportion of patients with moderate-severe exacerbations among the FEE
Fig 2. Distribution of phenotypes by age and gender.
doi:10.1371/journal.pone.0160770.g002
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and FECB phenotypes. After one-year of follow-up, 97% of NE phenotype and nearly half
(49.8%) of patients with frequent exacerbations (FEE, FECB or 0) remained in the same pheno-
type (Fig 4).
Finally, sixty-seven deaths were observedduring one-year of follow-up, with no differences
between phenotypes (p log rank Kaplan Mayer 0.156, Fig 5). However, note that the compari-
son of one-year mortality of the extreme groups FECB vs ACOS was significant with a
p = 0.026, but not so within the other two. The causes of death were respiratory failure (15
patients), lung cancer (12), other cancer (7), cardiovascular disease (7), pneumonia (3), COPD
exacerbation (1), other causes (5) and unknown (17) (data not shown).
Discussion
We have reported the clinical characteristics and distribution of previously proposed clinical
phenotypes in a large cohort of COPD patients followed-up for one year. The GesEPOCpro-
posed approach separates patients by severity of airway obstruction and BODE, symptoms, the
presence of exacerbations, and emphysema, and by pharmacological treatment. However, a
small proportion of patients (2.3%) remained unclassified by this algorithm.Most patients clas-
sified according to these clinical phenotypes remained in the same category after one year of
Table 1. Demographic and clinical characteristics, by phenotype.
0 NE ACOS FEE FECB p
19 (2.3%) 550 (66.2%) 125 (15.0%) 38 (4.6%) 99 (11.9%)
Female, n (%) 2 (10.5) 90 (16.4) 23 (18.4) 12 (31.6) 14 (14.1) 0.126
Age, mean ± SD 69.0±9.4 67.4±9.1 66.5±8.7 68.4±8.7 69.5±8.1 0.113
Pack-year, mean ± DE 50.8±28.4 56.3±28.7 53.2±26.2 52.9±26.3 60.8±30.0 0.270
Current smoker, n (%) 2 (10.5) 156 (28.4) 44 (35.2) 10(26.3) 28 (28.3) 0.218
BMI, mean ± SD 28.7±4.8 28.0±5.7 29.0±5.5 28.0±4.8 27.8±4.8 0.367
Symptoms, n (%)
-cough and sputum 0 (0.0) 315 (57.3) 75 (60.0) 0 (0.0) 99 (100.0) <0.001
-dyspnea (mMRC >2) 10 (52.6) 233 (42.4) 56 (44.8) 16 (43.2) 67 (67.7) <0.001
CAT (m ± SD) 11.28±7 11.74±7 12.02±7,5 11.61±6,1 17.14±8,2 <0.001
FEV1%, m ± SD 58.2±19.8 60.7±21.1 61.2±18.1 55.3±15.7 52.9±19.4 0.004
FVC%, m ± SD 83.3±21.4 86.7±23.3 84.9±18.5 86.3±24.7 80.1±23.1 0.116
FEV1/FVC, m ± SD 53.1±12.6 52.9±11.5 54.8±10.9 49.1±9.9 49.2±10.9 0.001
Prevalence of GOLD airflow limitation, n (%) 0.074
GOLD I 2 (10.5) 104 (19.0) 21 (16.8) 3 (7.9) 11 (11.0)
GOLD II 11 (57.9) 263 (48.0) 69 (55.2) 21 (55.3) 39 (39.4)
GOLD III 4 (21.1) 120 (21.9) 25 (20.0) 10 (26.3) 29 (29.3)
GOLD IV 2 (10.5) 61 (11.1) 10 (8.0) 4 (10.5) 20 (20.2)
BODE, mean ± SD 1.8±1.6 1.9±1.8 1.9±1.8 2.0±1.7 3.0±2.5 <0.001
BODE quartile, n (%) 0.001
0–2 12 (70.6) 357 (68.8) 78 (65.5) 26 (70.3) 45 (47.9)
3–4 3 (17.6) 114 (22.0) 33 (27.7) 9 (24.3) 26 (27.7)
5–6 2 (11.8) 39 (7.5) 5 (4.2) 1 (2.7) 16 (17.0)
7–10 0 (0.0) 9 (1.7) 3 (2.5) 1 (2.7) 7 (7.4)
DLCO <80%, n (%) 0 (0.0) 242 (44.0) 50 (40.0) 25 (65.8) 47 (47.5) <0.001
Emphysema by CT scan, n/N (%) 0/2 (0%) 125/197 (63.5%) 19/35 (54.3%) 17/19 (89.5%) 25/34 (73.5%) 0.019
Moderate-severe exacerbation in previous year, n (%) 9 (47.4) 39 (7.1) 22 (17.6) 25 (65.8) 73 (76.7) <0.001
doi:10.1371/journal.pone.0160770.t001
Distribution of Clinical Phenotypes in a COPD Cohort
PLOS ONE | DOI:10.1371/journal.pone.0160770 September 29, 2016 7 / 15
follow-up. Moreover, the FECB phenotype was the most symptomatic with higher BODE score
and showed a trend to worse survival after one year.
Interpretation of novel findings
Clinical phenotypes in COPD have been defined as a single or combination of disease attri-
butes that describe differences between individuals with COPD as they relate to clinically
meaningful outcomes (symptoms, exacerbations, response to therapy, rate of disease progres-
sion or death) [2]. Our results demonstrate that the proposed GesEPOCphenotypes are associ-
ated to meaningful outcomes such as CAT, BODE, lung function, or exacerbations. Although
patients in our cohort were not treated according to a phenotype-based strategy, they show dif-
ferences in pharmacological treatments among the different phenotypes, which reflect the
application of personalizedmedicine in daily clinical practice, even at a time when lung func-
tion-based guidelines were used. Interestingly, ACOS did not have the highest proportion of
patients on inhaled corticosteroids, since it was not specifically recognizedby the current
guidelines at the time of recruitment.
Nevertheless, the proposed algorithm leaves a number of patients (2.3%) without a clear
phenotype other than frequent exacerbator, without chronic bronchitis or emphysema. This
also happens when trying to apply the Spanish GesEPOCphenotype-based guideline in a daily
clinical basis and probably is reflecting a pool of patients in whom exacerbations are triggered
Table 2. Distribution of selected comorbidities, by phenotype.
0 NE ACOS FEE FECB p
19 (2.3%) 550 (66.2%) 125 (15.0%) 38 (4.6%) 99 (11.9%)
Charlson, mean ± SD 1.6±1.7 1.2±1.5 1.2±1.6 1.2±1.5 1.6±1.7 0.361
Asthma, n (%) 0 0 28 (22.4) 0 0 <0.001
Dislypemia, n (%) 7 (36.8) 172 (31.3) 46 (36.8) 17 (44.7) 33 (33.3) 0.399
Diabetes, n (%) 3 (15.8) 100 (18.2) 25 (20.0) 5 (13.2) 19 (19.2) 0.902
Cardiopatı´a, n (%) 3 (15.8) 86 (15.6) 14 (11.2) 5 (13.2) 18 (18.2) 0.654
OSA, n (%) 2 (10.5) 59 (10.7) 15 (12.0) 2 (5.3) 9 (9.1) 0.800
Anxiety, mean ± SD 10.1±5.4 11.1±5.0 10.7±4.8 11.1±5.0 12.0±4.4 0.343
Anxiety, n (%) 0.285
- no 5 (33.3) 121 (26.2) 27 (24.8) 8 (24.2) 14 (15.6)
-potential 3 (20.0) 84 (18.2) 28 (25.7) 7 (21.2) 16 (17.8)
-confirmed 7 (46.7) 257 (55.6) 54 (49.5) 18 (54.5) 60 (66.7)
Depression, mean ± SD 7.9±5.4 8.6±4.6 8.3±4.9 8.5±4.9 9.7±5.3 0.313
Depression, n (%) 0.650
-no 7 (46.7) 204 (48.1) 49 (48.0) 14 (50.0) 33 (38.4)
-potential 4 (26.7) 68 (16.0) 17 (16.7) 3 (10.7) 13 (15.1)
-confirmed 4 (26.7) 152 (35.8) 36 (35.3) 11 (39.3) 40 (46.5)
doi:10.1371/journal.pone.0160770.t002
Table 3. Distribution of respiratory medication use, by phenotype.
0 NE ACOS FEE FECB p
19 (2.3%) 550 (66.2%) 125 (15.0%) 38 (4.6%) 99 (11.9%)
Anticholinergics, n (%) 18 (94.7) 398 (72.5) 82 (65.6) 33 (86.8) 88 (88.9) <0.001
Beta2-agonists, n (%) 15 (78.9) 396 (72.0) 91 (72.8) 32 (84.2) 85 (85.9) 0.029
Inhaled steroids, n (%) 14 (73.7) 344 (62.5) 79 (63.2) 29 (76.3) 78 (78.8) 0.009
Theophylline, n (%) 6 (31.6) 43 (7.8) 6 (4.8) 4 (10.5) 18 (18.2) <0.001
doi:10.1371/journal.pone.0160770.t003
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by other comorbid conditions, since they show the highest Charlson score (Table 2), similar to
FECB patients.
Fig 3. Baseline and one-year scores for CAT (panel A) and BODE (panel B).
doi:10.1371/journal.pone.0160770.g003
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Previous studies
Other groups have previously shown that different COPD phenotypes are related to clinically
meaningful outcomes. Soler-Cataluña et al. demonstrated that patients with frequent exacerba-
tions have worse survival than non-exacerbator patients [13]. This was further explored by
Hurst et al. in the ECLIPSE cohort [3] demonstrating that exacerbations becamemore frequent
(and more severe) as the severity of COPD increased and that the single best predictor of exac-
erbations, across all GOLD stages, was a history of exacerbations. Our results are in keeping
with those previous observations.
Fig 4. Baseline and one-year distribution of phenotypes.
doi:10.1371/journal.pone.0160770.g004
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ACOS is now recognized as a distinct COPD clinical phenotype, and deserves special atten-
tion in international guidelines for both diseases, namely GOLD and GINA [14]. We have pre-
viously shown that the clinical criteria used to define ACOS in the present study are useful and
easy to apply in this cohort [12]. Prevalence of ACOS found here (15%) is similar to previously
described in other cohorts such as COPDGene (13%)[4]. Differences in clinical outcomes in
this specific phenotype are discussed elsewhere [12].
Chronic bronchitis has also been associated with worse respiratory symptoms and higher
risk of exacerbations in well-characterized cohorts of COPD patients such as COPDGene [15]
or PLATINO [16].
Emphysema is associated to mortality in COPD patients [17]. Different cluster analysis
studies have identified a cluster of patients at very low risk of mortality, who had mild
Fig 5. Kapplan-Mayer survival curve by phenotype.
doi:10.1371/journal.pone.0160770.g005
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respiratory disease and low rates of comorbidities and a different cluster with emphysema and
higher risk of mortality [18,19]. Rennard et al demonstrated that a cluster of patients with
severe emphysema, low FEV1 and the highest exacerbation and COPD hospitalization rate was
present in the ECLIPSE cohort [20]. We have shown here that these phenotypic characteristics
are stable when evaluating them after one year.
The distribution of the four clinical phenotypes proposed here has been recently described
in a cross-sectional study [8] with similar proportion to our population: 60.6% non-exacerba-
tors, 15.9% ACOS patients, 19.3% exacerbators with chronic bronchitis and 4.3% exacerbators
without chronic bronchitis. In this study, different phenotypes showed different demographic
and clinical characteristics as well as impact on health-related quality of life and mood.
Clinical implications
The recognition of a predominant phenotypemay help to guide the best therapeutic option for
a single patient, and this is the rationale for the novel approach of phenotype-oriented guide-
lines [7,21,22]. However, the proposals are based in expert consensus based on literature review
and clinical expertise, since no evidence exists proving that a phenotype approach is better
than the currently recommended approach based on lung function, symptoms and exacerba-
tions [1]. Our study demonstrates that a phenotype-based classification is easy to apply in a
majority of COPD patients, and shows the distribution and clinical characteristics of patients
classified by a clinical algorithm. Those patients with frequent exacerbations and no clear
emphysema or chronic bronchitis are likely to be related with comorbidities, as other cohorts
have previously identified in cluster analysis [18].
The approach based on phenotypes could be different to the current international recom-
mendations when we look at survival. As a sentivity analysis, we compared the survival curves
of the four GesEPOCproposed phenotypes (Fig 5), with the latest GOLD 2013 staging, that
includes CAT, mMRC and CCQ to assess the symptoms domain (data not shown). The GOLD
2013 staging had a better prognostication for 1-year mortality (log-rank test = 0.004) versus
the GesEPOC staging (log-rank test = 0.156), but with a greater mortality in B than C stages,
which severely limits its usability, as highlighted elsewhere [23].
Limitations
Our study has several limitations. Firstly, although patients from this well-characterized cohort
are classified by a clinical algorithm into different phenotypes, patients may share characteris-
tics of different phenotypes at the same time, which could lead to a different staging along the
natural history of the patient´s disease. However, phenotype characteristics remained reason-
ably stable, at least, after one-year of follow-up. Moreover, to address the factors that shift
patients from one to other phenotype would be of interest but it was beyond the scope of our
study. Secondly, there is a loss of patients during follow-up that could bias the interpretation of
outcomes. This fact is also affecting the analysis of survival, and, added to the low number of
deaths observed, could justify the lack of differences in the analysis of mortality. And thirdly,
our patients are treated according to the current guidelines by the time of recruitment, but
most likely also according to physician judgment, which could imply a kind of “phenotyping”
patients already.
Conclusions
We have shown that there is an uneven distribution of COPD phenotypes in stable COPD
patients, with significant demographic, clinical, and use of health resources differences. The
differences observed remain stable after one-year of follow up. The phenotype approach helps
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the clinician to identify the patients that can benefit more of a specific treatment. Further stud-
ies are needed to demonstrate whether this approach is associated with better clinical outcomes
than the current approach based on lung function, symptoms and exacerbations.
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